Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metabolism‐focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer

27 Feb 2024

Abstract excerpt

Homologous recombination (HR) and poly ADP-ribosylation are partially redundant pathways for the repair of DNA damage in normal and cancer cells. In cell lines that are deficient in HR, inhibition of poly (ADP-ribose) polymerase (poly (ADP-ribose) polymerase [PARP]1/2) is a proven target with several PARP inhibitors (PARPis) currently in clinical use. Resistance to PARPi often develops, usually involving genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38411275
DOI: 10.1002/mc.23705

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metabolism‐focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancerPMID 38411275Read ↗

Metabolism-focused CRISPR screen unveils Mitochondrial Pyruvate Carrier 1 as a critical driver for PARP inhibitor resistance in lung cancerSemantic proximity Read ↗

Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivitySemantic proximity Read ↗

ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells.Semantic proximity Read ↗

Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibitionSemantic proximity Read ↗

Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired ResistanceSemantic proximity Read ↗

A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor ResistanceSemantic proximity Read ↗

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitorsSemantic proximity Read ↗

Metabolically inducing defects in DNA repair sensitizes BRCA –wild-type cancer cells to replication stressSemantic proximity Read ↗

Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancerSemantic proximity Read ↗

A quantitative chemotherapy genetic interaction map reveals new factors associated with PARP inhibitor resistanceSemantic proximity Read ↗

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistanceSemantic proximity Read ↗

Enhancing cisplatin drug sensitivity through PARP3 inhibition: The influence on PDGF and G-coupled signal pathways in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.